Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: Converging evidence from phase II trials

PURPOSE: Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study we demonstrate that recurrent GBM patients with a specific diffusion MR imaging signature have an overall survival (OS) advantage when treated with cediranib, bevacizumab, cabozan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ellingson, Benjamin M., Gerstner, Elizabeth R., Smits, Marion, Huang, Raymond Y., Colen, Rivka, Abrey, Lauren E., Aftab, Dana T., Schwab, Gisela M., Hessel, Colin, Harris, Robert J., Chakhoyan, Ararat, Gahrmann, Renske, Pope, Whitney B., Leu, Kevin, Raymond, Catalina, Woodworth, Davis C., de Groot, John, Wen, Patrick Y., Batchelor, Tracy T., van den Bent, Martin J., Cloughesy, Timothy F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626594/
https://ncbi.nlm.nih.gov/pubmed/28655794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2844
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados